Monopar Therapeutics (MNPR) Competitors $40.69 -0.49 (-1.19%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$40.56 -0.13 (-0.31%) As of 08/1/2025 04:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock MNPR vs. RCUS, PHVS, SYRE, AVDL, AMPH, MENS, IOVA, ELVN, AVXL, and GPCRShould you be buying Monopar Therapeutics stock or one of its competitors? The main competitors of Monopar Therapeutics include Arcus Biosciences (RCUS), Pharvaris (PHVS), Spyre Therapeutics (SYRE), Avadel Pharmaceuticals (AVDL), Amphastar Pharmaceuticals (AMPH), Jyong Biotech (MENS), Iovance Biotherapeutics (IOVA), Enliven Therapeutics (ELVN), Anavex Life Sciences (AVXL), and Structure Therapeutics (GPCR). These companies are all part of the "pharmaceutical products" industry. Monopar Therapeutics vs. Its Competitors Arcus Biosciences Pharvaris Spyre Therapeutics Avadel Pharmaceuticals Amphastar Pharmaceuticals Jyong Biotech Iovance Biotherapeutics Enliven Therapeutics Anavex Life Sciences Structure Therapeutics Monopar Therapeutics (NASDAQ:MNPR) and Arcus Biosciences (NYSE:RCUS) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, media sentiment, analyst recommendations, risk, dividends and valuation. Is MNPR or RCUS more profitable? Monopar Therapeutics has a net margin of 0.00% compared to Arcus Biosciences' net margin of -258.94%. Monopar Therapeutics' return on equity of -55.39% beat Arcus Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Monopar TherapeuticsN/A -55.39% -51.53% Arcus Biosciences -258.94%-70.58%-32.97% Do institutionals and insiders believe in MNPR or RCUS? 1.8% of Monopar Therapeutics shares are owned by institutional investors. Comparatively, 92.9% of Arcus Biosciences shares are owned by institutional investors. 20.5% of Monopar Therapeutics shares are owned by insiders. Comparatively, 9.6% of Arcus Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Which has better valuation & earnings, MNPR or RCUS? Monopar Therapeutics has higher earnings, but lower revenue than Arcus Biosciences. Monopar Therapeutics is trading at a lower price-to-earnings ratio than Arcus Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMonopar TherapeuticsN/AN/A-$15.59M-$3.48-11.69Arcus Biosciences$258M3.76-$283M-$4.19-2.19 Does the media favor MNPR or RCUS? In the previous week, Arcus Biosciences had 3 more articles in the media than Monopar Therapeutics. MarketBeat recorded 4 mentions for Arcus Biosciences and 1 mentions for Monopar Therapeutics. Arcus Biosciences' average media sentiment score of 0.53 beat Monopar Therapeutics' score of 0.00 indicating that Arcus Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Monopar Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Arcus Biosciences 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Do analysts prefer MNPR or RCUS? Monopar Therapeutics presently has a consensus target price of $60.00, indicating a potential upside of 47.46%. Arcus Biosciences has a consensus target price of $21.29, indicating a potential upside of 132.38%. Given Arcus Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Arcus Biosciences is more favorable than Monopar Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Monopar Therapeutics 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83Arcus Biosciences 0 Sell rating(s) 2 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.89 Which has more risk and volatility, MNPR or RCUS? Monopar Therapeutics has a beta of 1.05, suggesting that its share price is 5% more volatile than the S&P 500. Comparatively, Arcus Biosciences has a beta of 0.89, suggesting that its share price is 11% less volatile than the S&P 500. SummaryArcus Biosciences beats Monopar Therapeutics on 10 of the 16 factors compared between the two stocks. Get Monopar Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MNPR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MNPR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MNPR vs. The Competition Export to ExcelMetricMonopar TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$251.82M$3.00B$5.49B$9.52BDividend YieldN/A2.43%4.73%4.09%P/E Ratio-11.6917.6228.7823.81Price / SalesN/A179.21372.2066.04Price / CashN/A41.9535.4557.96Price / Book4.518.508.275.54Net Income-$15.59M-$55.06M$3.25B$259.28M7 Day Performance-9.52%-3.99%-3.70%-4.64%1 Month Performance15.73%9.58%4.34%4.41%1 Year Performance1,072.62%6.70%25.90%17.95% Monopar Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MNPRMonopar Therapeutics1.9638 of 5 stars$40.69-1.2%$60.00+47.5%+1,074.0%$251.82MN/A-11.6910Upcoming EarningsRCUSArcus Biosciences2.1458 of 5 stars$9.85-3.7%$21.29+116.1%-41.8%$1.08B$258M-2.35500Upcoming EarningsPHVSPharvaris1.7483 of 5 stars$20.00-3.0%$36.20+81.0%+25.5%$1.08BN/A-6.6430SYRESpyre Therapeutics2.3063 of 5 stars$16.98-4.6%$53.40+214.5%-39.6%$1.07BN/A-4.5073News CoverageUpcoming EarningsGap DownAVDLAvadel Pharmaceuticals2.6715 of 5 stars$10.83-1.8%$18.33+69.3%-32.9%$1.07B$169.12M-40.1170News CoverageUpcoming EarningsAMPHAmphastar Pharmaceuticals4.3707 of 5 stars$22.24-0.6%$32.33+45.4%-50.0%$1.05B$731.97M8.062,028News CoverageUpcoming EarningsMENSJyong BiotechN/A$14.48+4.9%N/AN/A$1.05BN/A0.0031Positive NewsQuiet Period ExpirationIOVAIovance Biotherapeutics4.4649 of 5 stars$2.95-5.8%$12.22+314.3%-67.2%$1.05B$164.07M-2.38500Upcoming EarningsGap DownELVNEnliven Therapeutics2.469 of 5 stars$20.67-2.5%$41.20+99.3%-24.2%$1.04BN/A-10.7750AVXLAnavex Life Sciences3.7852 of 5 stars$11.57-4.6%$44.00+280.3%+70.2%$1.04BN/A-21.0440News CoveragePositive NewsUpcoming EarningsHigh Trading VolumeGPCRStructure Therapeutics2.0602 of 5 stars$18.27+1.8%$76.17+316.9%-51.7%$1.03BN/A-21.00136News CoverageUpcoming Earnings Related Companies and Tools Related Companies Arcus Biosciences Alternatives Pharvaris Alternatives Spyre Therapeutics Alternatives Avadel Pharmaceuticals Alternatives Amphastar Pharmaceuticals Alternatives Jyong Biotech Alternatives Iovance Biotherapeutics Alternatives Enliven Therapeutics Alternatives Anavex Life Sciences Alternatives Structure Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MNPR) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredA new rule goes live in July — and the banks are quietly crushing itA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Monopar Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Monopar Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MNPR Stock Alerts